Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.74 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.74 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661352 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL6253593 | 0.89 | ADORA2A (0.80) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL6685504 | 0.87 | ADORA3 (0.78) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL6660602 | 0.87 | ADORA3 (0.86) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL6660596 | 0.87 | ADORA3 (0.86) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL7067723 | 0.87 | ADORA1 (0.77) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL7067730 | 0.87 | ADORA1 (0.77) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL7067593 | 0.87 | ADORA1 (0.77) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL7067588 | 0.87 | ADORA1 (0.77) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 | |
| SCHEMBL6661148 | 0.85 | ADORA3 (0.75) | ADORA3ADORA2AADORA1ADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1457495-A1 | Adenosine A1 receptor agonists | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | claimed |
| US-6455510-B1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | claimed |
| EP-1030857-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | claimed |
| WO-1999024449-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| EP-1457495-A1 | Adenosine A1 receptor agonists | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | disclosed |
| EP-1030857-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030004126-A1 | Formulations of adenosine A1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| EP-1248632-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2002-10-16 | — | — | EP | disclosed |
| US-6455510-B1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| WO-2001045715-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-1030857-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024449-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004126-A1 | Formulations of adenosine A1 agonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.